Sequenom, Inc. (NASDAQ:SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced that its shareholders elected Catherine J. Mackey, Ph.D., as a new member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been appointed to the Audit and Nominating and Corporate Governance committees of the Company’s Board of Directors.
“We are pleased to welcome Dr. Mackey to our board, and we look forward to drawing on her more than 30 years of executive leadership and strong expertise in research and development as we expand our testing portfolio and drive continued growth for the company,” said Kenneth F. Buechler, Ph.D., Chairman of Sequenom, Inc.’s Board of Directors.
Dr. Mackey is currently the Chief Executive Officer of CYPrus Therapeutics, Inc., a privately-held small molecule pharmaceutical development company. She is a Special Advisor to Fortis Advisors LLC, and serves on the Scientific Advisory Boards of FHOOSH, Inc. and Cypher Genomics. In addition, Dr. Mackey is a director and a member of the Finance and Audit & Compliance Committees of Rady Children’s Hospital and is past-chair of CONNECT. Dr. Mackey currently serves on the boards of privately-held companies Cour Pharmaceutical Development Company (Chair), Evolve Biosystems, Inc. and Viventia Bio, Inc.
Prior to her current roles, Dr. Mackey served as the Senior Vice President of Worldwide Research and Development at Pfizer Inc. from 2001 through 2010 and is credited with leading Pfizer’s La Jolla Labs to become one of Pfizer’s most successful R&D sites. Before that, Dr. Mackey was Vice President of Strategic Alliances at Pfizer’s R&D headquarters inConnecticut and the Leader of Genomic and Proteomic Sciences at Pfizer. Leading up to her time at Pfizer, Dr. Mackey held positions of increasing responsibility for DEKALB Genetics including Vice President and Head of Research and Development.
Dr. Mackey received her B.S. and Ph.D. degrees in microbiology from Cornell University. (Original Source)
Shares of Sequenom closed yesterday at $3.2 . SQNM has a 1-year high of $4.80 and a 1-year low of $2.74. The stock’s 50-day moving average is $3.67 and its 200-day moving average is $3.74.
On the ratings front, Sequenom has been the subject of a number of recent research reports. In a report issued on May 8, Oppenheimer analyst Ling Wang reiterated a Buy rating on SQNM. Separately, on May 7, Wedbush’s Zarak Khurshid downgraded the stock to Hold and has a price target of $4.50.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ling Wang and Zarak Khurshid have a total average return of -2.0% and 6.1% respectively. Wang has a success rate of 43.2% and is ranked #3021 out of 3632 analysts, while Khurshid has a success rate of 68.2% and is ranked #1111.
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.